Abstract The reasons for persistent brain dysfunction in chronically HIV-infected persons on stable combined antiretroviral therapies (CART) remain unclear. Host and viral factors along with their interactions were examined in 260 HIV-infected subjects who underwent magnetic resonance spectroscopy (MRS). Metabolite concentrations (NAA/Cr, Cho/Cr, MI/Cr, and Glx/Cr) were measured in the basal ganglia, the frontal white matter, and gray matter, and the best predictive models were selected using a bootstrap-enhanced Akaike information criterion (AIC). Depending on the metabolite and brain region, age, race, HIV RNA concentration, ADC stage, duration of HIV infection, nadir CD4, and/or their interactions were predictive of metabolite concentrations, particularly the basal ganglia NAA/Cr and the mid-frontal NAA/ Cr and Glx/Cr, whereas current CD4 and the CPE index rarely or did not predict these changes. These results show for the first time that host and viral factors related to both current and past HIV status contribute to persisting cerebral metabolite abnormalities and provide a framework for further understanding neurological injury in the setting of chronic and stable disease.
Background
HIV infection is associated with distinct pathological and cellular changes in the brain resulting in neurocognitive, motor, and behavioral disturbances, including dementia, collectively referred to as the AIDS dementia complex (ADC) (Navia et al. 1986a, b) or HIV-associated neurocognitive disorder (HAND) (Antinori et al. 2007 ). Since the introduction of combination antiretroviral therapy (CART), the incidence of HIV-associated dementia (HAD) has declined significantly (Palella et al. 1998; Hammer et al. 2006; Sacktor et al. 2002 , Robertson et al. 2007 Tozzi et al. 2007 ). Nevertheless, an emerging body of evidence from neuroimaging, clinical, and pathological studies suggests that despite remarkable advances in treatment, central nervous system (CNS) dysfunction in the context of chronic and stable HIV persists and may continue to unfold despite successful systemic therapy (Heaton et al. 2010; Heaton et al. 2011; Harezlak et al. 2011; Cardenas et al. 2009; Cohen et al. 2010a, b; Tate et al. 2011) .
The HIV Neuroimaging Consortium was formed to prospectively assess rates and patterns of brain injury and cognitive impairment among chronically infected subjects on CART. We recently examined the possibility that residual injury persists in these patients by proton magnetic resonance spectroscopy (MRS) Cohen et al. 2010a ). MRS provides a sensitive and useful in vivo method to detect changes in cellular metabolism across multiple brain regions in both HIV-infected subjects and SIV-infected macaque at different stages of infection and neurocognitive impairment Cohen et al. 2010a; Meyerhoff et al. 1994; Tracey et al. 1996; Lopez-Villegas et al. 1997; Salvan et al. 1997; Chang et al. 2002; Chang et al. 2004; Yiannoutsos et al. 2004; Paul et al. 2007; Mohamed et al. 2010) . Abnormalities have included increases in choline (Cho)/Cr (creatine) or Cho, a marker of membrane integrity and myo-inositol (MI)/Cr or MI, a marker of glial cell activity, along with decreases in Nacetylaspartate (NAA/Cr) or NAA, a marker of neuronal integrity in deep white matter and gray matter structures, particularly the basal ganglia. Decreases in NAA/Cr or NAA have been correlated with the severity of NCI, consistent with previously reported clinical-pathological findings . Both increases and decreases in Glx reflecting glutamate and glutamine levels have been reported, but the clinical significance of these findings remains unclear . MRS-derived metabolites were acquired from the basal ganglia, frontal white matter, and mid-frontal cortex in 240 HIV-infected subjects and revealed the persistence of inflammation (increases in Cho and MI) in both neuroasymptomatic and subjects with cognitive impairment (ADC) across all regions when compared to age-matched healthy controls despite stable antiretroviral treatment . Neuronal injury or loss (a decrease in NAA/Cr) was also observed but only in the ADC group, consistent with notion that decreases in NAA provide a robust in vivo biomarker of HIV-associated cognitive impairment Chang et al. 2004; Yiannoutsos et al. 2004) .
The specific host and disease-related factors contributing to these patterns of injury in the setting of an otherwise stable yet chronic disease are uncertain. In previous preCART studies, low current CD4 and detectable cerebrospinal fluid (CSF) HIV RNA levels were associated with HIV-related cognitive impairment (Ellis et al. 1997; McArthur et al. 1997) . Recently, we and others have shown significant associations between a history of advanced immunosuppression as reflected in the nadir CD4 count and HIV RNA concentrations with cognitive impairment and cortical atrophy (Heaton et al. 2010; Cohen et al. 2010a, b; Tate et al. 2011; Valcour et al. 2006) . In the present study, we hypothesized that patterns of brain injury as measured by MRS are associated with one or more host or disease-related factors or their interactions.
Methods
Details for the clinical and imaging assessments in addition to the demographic characteristics of the cohort can be found in Harezlak et al. (2011) .
Clinical assessments
Subjects were recruited to participate in a HIV Neuroimaging Consortium (HIVNC) longitudinal study of brain injury and neurocognitive impairment at the following sites: UCSD, UCLA, Harbor-UCLA, Stanford University, University of Colorado at Denver, University of Pittsburgh, and University of Rochester. Inclusion criteria included nadir CD4 count ≤200 cells/mL and stable antiretroviral regimen with any FDA-approved antiretroviral therapy (i.e., nucleoside, nonnucleoside, and/or protease inhibitors) for at least 12 consecutive weeks prior to study screening. Exclusion criteria included unstable medical disorders (hepatic, renal, metabolic), pre-morbid or co-morbid psychiatric disorders (bipolar disorder and active depression), and focal or diffuse neurologic disorders, including chronic seizures, stroke, head trauma resulting in loss of consciousness >30 min, and infection (except for HIV-1). Subjects with active alcohol and drug abuse or related medical complications within 6 months of study entry were excluded .
Assessments included magnetic resonance imaging and MRS, neurological and neuropsychological evaluations, and plasma and CSF assays for HIV RNA (Cohen et al. 2010a) . Cognitive status was assessed by a trained clinician using the ADC Staging as previously described (Price and Brew 1988) . ADC stage 0 (asymptomatic) denotes neurocognitively normal status, stage 0.5 refers to subclinical neuropsychological impairment only, stage 1 is symptomatic functional impairment, and stages 2 or greater indicate major impairment. Neuropsychological evaluation was performed in cognitive domains most implicated in HIV infection, including processing speed, verbal fluency, executive functioning, working memory, learning and memory, and psychomotor function (Heaton et al. 2004 ).
MRS methods
Single-voxel proton MRS spectra were acquired using the GE PRESS sequence from voxels 6 cc in volume in three brain regions as previously described: mid-line frontal gray, midfrontal centrum semiovale (white matter), and right (or left) basal ganglia (deep gray matter) . Field homogeneity and water suppression were adjusted using automated algorithms from GE. Water-suppressed spectra were collected with TE/TR=35/3,000 ms, bandwidth=2,500 Hz, 128 averages, NEX=8. The metabolite ratios NAA/Cr, Cho/Cr, MI/Cr, and Glx (=Glu + Gln)/Cr were determined using LCModel spectral analysis software and an unsuppressed water FID at TE=35 ms for eddy-current correction (Provencher 2001) . This automated processing method yields metabolite ratios with Cramer-Rao lower bound less than 20 % (Lee et al. 2003) .
Statistical methods
The primary analysis consisted of determining predictive factors for each of four metabolite ratio levels (NAA/Cr, Cho/Cr, MI/Cr, and Glx/Cr) in three brain regions (basal ganglia, frontal white matter, and mid-frontal cortex gray matter). We considered both host and disease-related factors in linear regression models treating the brain metabolite ratios as outcomes. Statistical modeling was performed to assess both additive effects and two-way interactions. We attempted to fit the most parsimonious model (the model containing the fewest predictors) while, at the same time, maximizing the predictive ability of the model, measured by the proportion of variability of the outcome variable (MRS metabolite ratio levels) accounted for by the model (expressed as the Rsquared in the regression model). Final additive and interaction linear regression models were selected by maximizing the Akaike information criterion (AIC), which balances model fit (maximum R-squared) and model complexity (minimum number of predictive factors simultaneously included in the model) (Akaike 1974) . To mitigate the tendency of the AIC to select models containing predictors which are not statistically significant, we used a bootstrap procedure starting with a model pre-selected as the best fit in the original dataset, by selecting bootstrap samples (Austin and Tu 2004) from the original dataset and repeating the fitting procedure. The bootstrap sample selection and fitting was repeated 500 times. A predictor (either additive or an interaction effect) was chosen for the final model if it were selected in at least 70 % of the bootstrapped samples. As the primary goal for this study was to identify predictive models and the associated predictors, conclusions were not based on separately testing each covariate's association with the brain metabolite level, and thus, no adjustments for multiple comparisons were made.
The choice of the candidate predictive factors was based on both the prior findings Cohen et al. 2010b; Harezlak et al. 2011) and their availability in the database. We included demographic factors (age, sex, race, education), disease-specific factors (ADC stage, duration of HIV infection, nadir and current CD4 count, plasma RNA), and treatment-specific factors (CNS penetration effectiveness or CPE score derived as previously described from an algorithm that considers the effectiveness of each agent in the antiretroviral regimen to cross the blood brain barrier) (Letendre et al. 2008) . In a separate analysis, we included CSF HIV RNA concentrations, available in 117 subjects.
Results

Subject characteristics
Summary statistics are provided for the 260 subjects who had at least 1 brain metabolite ratio out of 12 measured and an ADC assessment available. Age was the only demographic factor which differed significantly between ADC groups (Table 1) . However, there was no clear pattern of older age associated with advanced ADC stage. The median age of the cohort was 46 years with a median duration of infection of 12 years. All subjects had a history of advanced disease with a median nadir CD4 count of 35 cells/μL, but the median CD4 count at baseline was 307 cells/μL, consistent with an immunological response to CART. Most subjects received antiretroviral treatment for at least 1 year and had undetectable plasma HIV RNA levels ( Table 1) .
The availability of data for each metabolite varied depending on the metabolite and brain region. Most metabolites (excluding Glx) were missing less than 5 % of the values with the exception of basal ganglia metabolites where between 9 and 10 % of the values were missing. The remainder of the missing values included Glx/Cr in frontal white matter (FWM) 13 %, Glx/Cr in mid-frontal cortex (MFC) 15 %, and Glx/Cr in basal ganglia (BG) 27 %. The differences in missing patterns were not found to be associated with the ADC stage.
Modeling MRS metabolite ratios as functions of predictive variables
From the four metabolite ratios modeled in three brain regions (12 models), 7 models were found to contain both additive and interaction effects: NAA/Cr and MI/Cr in the frontal white matter (FWM), Cho/Cr, MI/Cr, and Glx/Cr in the basal ganglia (BG), and Cho/Cr and Glx/Cr in the mid-frontal cortex (MFC ; Tables 2 and 3 ). In the five remaining models (Cho/Cr and Glx/Cr in the FWM; NAA/Cr in BG; NAA/Cr and MI/Cr in MFC), only additive effects were observed ( Table 2 ). The most frequent demographic variables selected were age (8/12 models) and race-coded as white versus non-white race (4/12 models; Table 3 ). Among diseaserelated variables, ADC stage-coded as ADC stage 1-3 versus ADC stage 0 or 0.5-was selected in 5/12 models; detectable plasma RNA level-coded as undetectable versus detectable-was chosen in 5/12 models; duration of HIV infection in 4/12 models; and low nadir CD4 count-coded as high (greater than 50 cells/mL) versus low (50 cells/mL or less) in 3/12 (Table 3) . In contrast, current CD4 count was found in only in 1/12 models, and the CPE index was not significantly associated with any of the12 metabolite ratios. The interaction between age and ADC stage was present in 4/12 models, and the interaction between detectable plasma RNA level and low nadir CD4 count was found in 2/12 models. As shown in Table 2 , the best predictive model (adjusted R 2 =0.183, p value <0.001) was found for the NAA/Cr in the basal ganglia, and the next most strongly predictive model (adjusted R 2 =0.111, p value <0.001) involved NAA/Cr in the mid-frontal cortex. Details for these models are provided in "Models of metabolite change and their predictors within each brain region" section.
Models of metabolite change and their predictors within each brain region
N-acetylaspartate: a marker of neuronal integrity
Lower NAA/Cr levels in FWM (adjusted (adj.) R 2 =0.050, p value=0.002) were associated with older age, and the interaction of detectable plasma RNA level and low nadir CD4 count. Thus, older subjects with low nadir CD4 count and detectable plasma HIV RNA levels had the lowest NAA/Cr levels in the frontal white matter.
Decreases in NAA/Cr levels in the MFC (adj. R 2 =0.111, p value <0.0001) were also associated with older age in addition to longer duration of HIV infection, detectable plasma RNA levels, and a less than high school education level. (93) 51 (91) 45 (88) 221 (92) 0.529 ART drug classes H A A R T n a ï v e 9 5 6 2 0 0 . 4 1 1 H A A R T p l u s P I 8 7 3 8 3 7 1 6 2 HAART no PI 38 13 8 59 CPE score, median (IQR) 1.5 (1.0-2.4) 1.5 (1.0-2.5) 1.5 (1.5-2.5) 1.5 (1.0-2.5) 0.519 a CSF viral load measured in N=101 subjects b N=241 out of 260 subjects had information on HAART As described above, the strongest predictive model among the 12 considered was found for NAA/Cr in the BG. Independent predictive factors included ADC stage 1-3, detectable plasma RNA levels, less than high school education, and male sex.
Choline: a marker of membrane integrity
Cho/Cr in the FWM was weakly associated with gender (adj. R 2 =0.019, p value=0.016) such that slightly higher levels were found in males. Elevated levels of Cho/Cr in the mid-frontal cortex (adj. R 2 =0.072, p value=0.001) were associated with ADC stage 1-3, non-white race, duration of HIV infection, and complex interactions involving age and ADC stage, age and duration of HIV infection, as well as age and non-white race. Thus, Cho/ Cr levels were higher among young individuals with clinical ADC (ADC stage 1-3), increased slightly in aging individuals with longer duration of HIV infection but decreased among aging white individuals.
Higher Cho/Cr levels in the basal ganglia (adj. R 2 =0.054, p value=0.003) were associated with ADC stage 1-3, nonwhite race, shorter duration of HIV infection, and the interaction of age and ADC stage. Cho/Cr levels were higher among younger individuals with clinical ADC while levels decreased in older, neuroasymptomatic, and chronically infected individuals.
Myo-inositol: a marker of glial cell activity
MI/Cr levels in the MFC (adj. R 2 =0.018, p value=0.021) were associated only with race such that slightly higher levels would be expected among non-white study participants.
Levels in the BG were weakly associated (adj. R 2 =0.023, p value=0.041) with the interaction of age and ADC stage. MI/ Cr levels were higher in younger subjects with ADC stage 1-3, but as observed with Cho/Cr, were lower in older asymptomatic subjects, suggesting that increasing age may be associated with less of an inflammatory response in the brain.
Increased MI/Cr levels in the frontal white matter (adj. R 2 = 0.060, p value <0.001) were associated with detectable plasma RNA level, ADC stage 1-3, and the interaction of age and ADC stage such that MI/Cr levels were higher in younger subjects with clinical ADC and levels in the BG, and again lower in older asymptomatic subjects.
Glutamine + glutamate: a marker of neuronal-glia cell activity
Glx/Cr in the FWM was associated with age and race such that higher levels would be found in younger white subjects (adj. R 2 =0.058, p value=0.001).
In contrast, Glx/Cr levels in the BG were strongly associated (adj. R 2 =0.101, p value <0.001) with lower nadir CD4 count and an interaction between current CD4 count and duration of HIV infection, so that subjects with longer duration of HIV infection and lower baseline CD4 count had higher Glx/Cr levels.
The strongest predictive model of Glx/Cr was in the midfrontal cortex (adj. R 2 =0.117, p value <0.001). Older age and the interaction of detectable plasma RNA concentration and low nadir CD4 count were the factors most strongly associated with lower Glx/Cr levels. Thus, older subjects with low nadir CD4 count and detectable plasma HIV RNA levels showed the lowest Glx/Cr levels in this region.
Analysis including CSF HIV RNA
The same modeling strategy for the 12 metabolite ratios was applied to data obtained from 117 subjects with CSF HIV RNA assays with data in at least 1 of 12 metabolite-by-brainregion combinations. For the majority of the participants, the plasma and CSF HIV RNA detectable and undetectable status coincided. However, there were 12 patients with detectable plasma HIV RNA and undetectable CSF HIV RNA, and 4 with undetectable plasma and detectable CSF HIV RNA. CSF HIV RNA levels were included in the model along with all the previously listed demographic and disease-specific factors, including plasma HIV RNA levels. The findings are similar to those described above with the notable exception that CSF HIV RNA replaced plasma levels as the predictive factor in the majority of models. The two exceptions involved MI/Cr in the frontal white matter and Glx/Cr in the mid-frontal cortex.
Discussion
A number of in vivo studies prior to the advent of CART have shown significant cellular changes in the HIV-infected brain as measured by MRS, including inflammation primarily in the white matter with evidence of neuronal injury in the basal ganglia and cortex (Meyerhoff et al. 1994; Tracey et al. 1996; Lopez-Villegas et al. 1997; Salvan et al. 1997; Chang et al. 2002; Chang et al. 2004; Yiannoutsos et al. 2004 ). More recently, we have shown that these changes persist in chronically infected patients despite restoration of immunological status and effective viral suppression in response to antiretroviral therapies Cohen et al. 2010a, b; Tate et al. 2011 ). The current study was directed at determining the demographic and clinical factors associated with the persistence of brain injury as measured by these metabolite abnormalities. The results show for the first time that events associated with these changes are likely to be multifactorial, driven by one or more hosts and disease-related factors as well as their interactions in a metabolite and region dependent manner. As the majority of subjects were neuroasymptomatic at the time of the MRS assessment, these results further suggest that specific patterns of brain abnormalities may be amplified in the context of antiretroviral treatment and chronic HIV infection, independent of cognitive status. Age was the most consistent factor, present in 66 % of the models. Several studies have suggested relationships between aging and the risk for specific neurological outcomes associated with HIV infection (Valcour et al. 2004; Ances et al. 2010; Becker et al. 2004 ). However, the relationship between age and specific brain patterns was more complex than might have been predicted and was modified by a number of factors, with ADC stage principal among them. Of note was the commonly observed interaction between ADC stage and age with regard to both inflammatory factors, Cho and MI, such that HIV-infected older patients showed lower levels of these metabolites compared to younger, cognitively impaired subjects. This is consistent with recent findings from a prospective study of the HIVNC cohort which showed significant decreases in choline (Navia et al. 2011) . Such changes may in part reflect attenuated immune-mediated responses with age or the effects of chronic treatment. Additional studies are needed to unravel the mechanisms contributing to these agerelated changes.
ADC stage, a robust clinical measure of cognitive impairment, which has been strongly correlated with other global measures including the global deficit score and the NPZ-8 (Paul et al. 2007 ) was the clinical factor most predictive of metabolite levels, notable decreases in NAA/Cr in the BG and MFC and increases in Cho or MI in all three regions but particularly in the BG. These findings not only reinforce the notion that functional disturbances in the basal ganglia are related to the extent of neurocognitive impairment Yiannoutsos et al. 2004 ) but also suggest that cortical involvement may contribute to clinical symptoms in the setting of chronic infection (Cardenas et al. 2009 ).
Of interest, ethnicity, and less commonly, education and gender were also associated with changes in specific metabolites. Non-white race was selected in models involving increases in Cho or MI, while less than a high school education was associated with NAA decreases in the BG and MFC. The relationship between level of education and NAA decreases is noteworthy as education attainment is a determinant of cognitive reserve, i.e., a person's capacity to resist the effects of brain disease or injury with preservation of cognitive functioning (Katzman 1993; Stern 2011; Satz et al. 1993) . High levels of education were found to be associated with less sensitivity to the effects of HIV in one of the early studies of cognitive reserve (Satz et al. 1993; Stern et al. 1996) , with subsequent studies providing empirical support for its protective effects in HIV Foley et al. 2012; Morgan et al. 2012; Shapiro et al. 2014) . Education level has also been linked to increased risk for neurodegenerative disorders such as Alzheimer's disease (Stern et al. 1996; Stern et al. 1999; Qiu et al. 2001; Manly et al. 2003; Karp et al. 2004; Stern 2006; Tucker and Stern 2011) . Cognitive reserve has also been linked to brain reserve; the brain's capacity to maintain functioning when damage has occurred. Conversely, cognitive frailty occurs in the context of chronic medical illnesses such as HIV infection which increase vulnerability to functional decline in susceptible people due to aging or early neurodegenerative disease (Woods et al. 2013) . In this regard, chronically HIV-infected patients exhibit reduced dynamic range of their functional brain response on fMRI, which seems to correspond with reduced cognitive reserve and neural efficiency (Ernst et al. 2009; Chang et al. 2013; Caldwell in press) . The finding in this study extend previous reports as it suggests that lower cognitive reserve in chronically HIVinfected patients may be a risk factor for neuronal loss in brain regions linked to cognitive impairment in these patients.
Of the three clinical factors selected, one is directly associated with current disease status (detectable plasma RNA), while the other two, nadir CD4 and duration of infection, are related to disease history. The relationship of plasma RNA levels to changes in NAA/Cr in all three regions, especially when compared to its effects on other metabolites, underscores the notion that current viral replication contributes to neuronal injury. It is noteworthy that metabolite changes in the frontal cortex were also strongly associated with age, duration of infection, and nadir CD4, which mirror findings from an analysis of cerebral atrophy in these subjects showing that factors associated with history rather than current viral activity had a greater effect on cortical volume loss.
Recent reports have shown that nadir CD4 is an important determinant for the persistence of cerebral atrophy and cognitive impairment among chronically infected subjects (Cardenas et al. 2009; Hammer et al. 2006; Valcour et al. 2006) . In the present study, nadir CD4 was an important predictor in three models (NAA/Cr in FWM, Glx/Cr in MFC and BG), particularly in combination with HIV RNA levels. Together, these findings suggest that the degree of immunosuppression prior to initiating CART is a critical determinant of subsequent neurological injury and that early intervention (i.e., at higher levels of CD4) may be necessary to prevent such compromise, including the possibility of irreversible damage. The fact that duration of infection emerged as a predictor independent of age, indicates that chronic infection may be detrimental among both young and older patients, even when current viral load is suppressed and CD4 count is increased.
Recent studies suggest that antiretroviral regimens that contain agents with superior CNS penetration as measured by the CPE or central nervous system effectiveness score may be associated with lower rates of cognitive impairment (Smurzynski et al. 2011; Casado et al. 2014) . It is noteworthy, however that neither the CPE score nor the current CD4 count were significant predictors of metabolite levels, further supporting the observation that HIV-associated brain injury may persist, even unfold, in the setting of an otherwise stable HIV disease. Current CD4 levels were selected in only one model (Glx/Cr levels in the basal ganglia), suggesting that current immunological status is probably a less important factor associated with cellular injury than current viral RNA levels or some aspects of disease history (most notably nadir CD4 count). While differences in CNS penetration exist across different antiretroviral regimens (Letendre et al. 2008) , the findings from this study suggest that, contrary to what might have been anticipated, regimens that contain agents with better CNS penetration have little effect on current HIV-associated brain injury once neurological damage has occurred in the setting of advanced immune suppression.
The additional influence of adding CSF RNA into the models was assessed in secondary analyses and in none of the models both CSF and plasma levels were selected simultaneously. The fact that CSF RNA replaced plasma RNA as the predictor in all, but two models, extends an existing body of evidence which shows that CSF RNA is more strongly associated with neurological outcomes than plasma levels and suggests CSF HIV RNA concentration may provide a better biomarker of CNS dysfunction in these patients (Ellis et al. 1997 McArthur et al. 1997 . Although routine CSF monitoring may be difficult to implement in practice, results from large prospective multicenter studies such as the Alzheimer's Disease Neuroimaging Initiative suggest that this may be feasible with proper education and training (Siuciak et al. 2012) .
Results from the models of the individual metabolites suggest a number of interesting conclusions: The strength of the association of NAA/Cr, a marker of neuronal integrity, in the basal ganglia with ADC stage fits with the prevailing understanding of the impact of HIV infection on the brain, which points to the basal ganglia as a critical locus of HIV activity and emerging cognitive impairment (Rostasy et al. 1999; Brew et al. 1995; Navia and Rostasy 2005) . In recent studies, based on a principal component analysis, we have shown that a neuronal factor derived from NAA/Cr levels measured in the basal ganglia is highly associated with risk for HIV-related cognitive impairment . Further, in a recent prospective MRS study of the HIVNC cohort, reduced NAA/Cr in the basal ganglia was the strongest predictor for the development of neurocognitive impairment among asymptomatic subjects followed over 2 years.
The strength of the association of Glx/Cr with the same clinical factors in various models, including HIV RNA and nadir CD4, which are similar to the case of NAA, points to the potential importance of glutamate and glutamine in HIVrelated neuropathogenesis. This observation has received further support from recent studies which have reported reduced levels of Glx in the frontal white matter or cortex in NA subjects as well as significant decreases in Glx over time in these subjects, suggesting that a change in this metabolite may represent an early event associated with HIV involvement of the brain Navia et al. 2011) .
The findings from this study illustrate how varying metabolic patterns across the HIV-infected brain can be examined in relationship to clinical and laboratory measures. The study demonstrates that host and viral factors, particularly those linked to current disease status and HIV disease history along with their interactions, are predictive of specific patterns of metabolite abnormalities that reflect pathological processes occurring in the chronically infected and treated brain. However, other factors not examined in these models may also be contributing to these changes, including the effects of various chemokines (Navia and Rostasy 2005; Letendre et al. 2011; Kaul and Lipton 1999) and co-morbid disorders such as hepatitis C and cardiovascular risk factors (Letendre et al. 2004; Valcour et al. 2005; van Gorp and Hinkin 2005; Perry et al. 2008; Ances et al. 2009 ) which have been associated with cognitive impairment or brain injury. Future studies will address the relative contributions of these factors to patterns of brain injury and cognitive impairment.
The predictive modeling employed in this study provides a sensitive methodological approach for determining the specific clinical factors affecting this pathology, which ultimately may have considerable clinical value with additional validation of these models. The application of these models to identify clinical, immunological, and viral predictors of longitudinal change in cerebral and cognitive function will be an important next step in determining which factors are most predictive of evolving brain disturbances in the setting of chronic HIV disease and CART.
